Published in Antimicrob Agents Chemother on August 08, 2011
Pulsed EPR characterization of HIV-1 protease conformational sampling and inhibitor-induced population shifts. Phys Chem Chem Phys (2016) 0.76
Comparison of genotypic and virtual phenotypic drug resistance interpretations with laboratory-based phenotypes among CRF01_AE and subtype B HIV-infected individuals. J Med Virol (2015) 0.75
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother (1998) 5.64
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol (2006) 2.33
Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology (1995) 2.29
Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey. AIDS (2007) 1.81
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis (2004) 1.54
Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother (2000) 1.17
Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother (2007) 1.16
Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr (2004) 1.13
Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev (2006) 1.11
Tipranavir-ritonavir genotypic resistance score in protease inhibitor-experienced patients. Antimicrob Agents Chemother (2008) 1.09
Trends of prevalence of primary HIV drug resistance in Germany. J Antimicrob Chemother (2007) 1.06
Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol (1994) 1.02
Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG. Antivir Ther (2006) 0.97
HIV-1 subtypes and response to combination antiretroviral therapy in Europe. Antivir Ther (2006) 0.96
Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms. AIDS (2008) 0.93
Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS (2008) 0.92
Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. Antimicrob Agents Chemother (2010) 0.90
Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay. J Med Virol (2003) 0.89
HIV-1 genotyping: comparison of two commercially available assays. Expert Rev Mol Diagn (2004) 0.81
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir. Antimicrob Agents Chemother (2011) 0.81
Tipranavir resistance associated mutations in protease inhibitor-naïve patients with HIV-1 subtype A/E infection. J Clin Virol (2008) 0.78
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79
Phylogenetic analysis of HIV-1 transmission: pol gene sequences are insufficient to clarify true relationships between patient isolates. AIDS (2004) 2.59
Is transmission of HIV-1 in non-viraemic serodiscordant couples possible? Antivir Ther (2008) 2.21
Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS (2010) 2.03
HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.94
The management of needlestick injuries. Dtsch Arztebl Int (2013) 1.89
Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann Intern Med (2003) 1.75
Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med (2002) 1.70
Evaluation of the Cobas AmpliPrep/Cobas Amplicor HIV-1 Monitor Ultrasensitive Test: comparison with the Cobas Amplicor HIV-1 Monitor test (manual specimen preparation). J Clin Virol (2002) 1.63
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis (2010) 1.54
HIV-2EU: supporting standardized HIV-2 drug resistance interpretation in Europe. Clin Infect Dis (2013) 1.49
Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients. Clin Infect Dis (2011) 1.49
The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia (2009) 1.49
Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir Ther (2009) 1.45
Multicenter evaluation of a new automated fourth-generation human immunodeficiency virus screening assay with a sensitive antigen detection module and high specificity. J Clin Microbiol (2002) 1.44
Accelerated telomere shortening in leukocyte subpopulations of patients with coronary heart disease: role of cytomegalovirus seropositivity. Circulation (2009) 1.41
[When viruses jump over species boundaries. Are dogs and cats to be permitted into bed?]. MMW Fortschr Med (2003) 1.41
Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr (2002) 1.37
Confirmation of putative HIV-1 group P in Cameroon. J Virol (2010) 1.36
Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma (2005) 1.36
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis (2014) 1.25
Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One (2012) 1.16
Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. Nephrol Dial Transplant (2004) 1.10
Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother (2005) 1.06
Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. J Electrocardiol (2010) 1.06
The threat of avian influenza A (H5N1). Part IV: Development of vaccines. Med Microbiol Immunol (2007) 1.06
Determination of risk of infection with blood-borne pathogens following a needlestick injury in hospital workers. Ann Occup Hyg (2008) 1.05
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis (2002) 1.05
Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol (2004) 1.04
Infection control management of patients with suspected highly infectious diseases in emergency departments: data from a survey in 41 facilities in 14 European countries. BMC Infect Dis (2012) 1.04
First transmission of human immunodeficiency virus Type 1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion (2009) 1.02
Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun (2005) 1.01
Rates of postoperative complications among human immunodeficiency virus-infected women who have undergone obstetric and gynecologic surgical procedures. Clin Infect Dis (2002) 1.01
A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. J Med Virol (2009) 1.00
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother (2006) 0.99
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol (2006) 0.99
Screening for infectious diseases at international airports: the Frankfurt model. Aviat Space Environ Med (2009) 0.98
Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures. J Virol Methods (2009) 0.98
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis. PLoS One (2013) 0.97
Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. Ann Intern Med (2015) 0.96
Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers. BMC Gastroenterol (2012) 0.95
Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus. J Med Chem (2005) 0.95
Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. Cancer Lett (2006) 0.93
A case of severe CMV-colitis in an HIV positive patient despite moderate immunodeficiency. Scand J Infect Dis (2003) 0.93
Construction and characterization of an HIV-1 group O infectious molecular clone and analysis of vpr- and nef-negative derivatives. Virology (2004) 0.93
Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins. Clin Cancer Res (2008) 0.93
Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency. AIDS (2008) 0.92
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS (2011) 0.91
The threat of avian influenza A (H5N1). Part I: Epidemiologic concerns and virulence determinants. Med Microbiol Immunol (2007) 0.91
Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. Med Microbiol Immunol (2009) 0.91
Research letter: is monitoring for CD4 counts still needed for the management of patients with long-term HIV RNA suppression? J Acquir Immune Defic Syndr (2012) 0.90
Prevalence- and gender-specific immune response to opportunistic infections in HIV-infected patients in Lesotho. Sex Transm Dis (2010) 0.89
A novel internally controlled real-time reverse transcription-PCR assay for HIV-1 RNA targeting the pol integrase genomic region. J Virol Methods (2007) 0.88
Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals. J Acquir Immune Defic Syndr (2004) 0.88
Malaria. Transfus Med Hemother (2008) 0.86
Deficiency of immunity to poliovirus type 3: a lurking danger? BMC Infect Dis (2012) 0.86
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PLoS One (2013) 0.86
Hepatitis E Virus. Transfus Med Hemother (2008) 0.86
Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antivir Ther (2008) 0.85
Influenza Virus. Transfus Med Hemother (2007) 0.85
Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease. Dis Colon Rectum (2014) 0.84
Phylogenetic analysis of acute hepatitis C virus genotype 4 infections among human immunodeficiency virus-positive men who have sex with men in Germany. Liver Int (2010) 0.84
Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice. Haematologica (2013) 0.84
Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting. Eur J Clin Pharmacol (2009) 0.84
Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany. BMC Infect Dis (2010) 0.84
Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen. Antivir Ther (2007) 0.83
Human Cytomegalovirus (HCMV) - Revised. Transfus Med Hemother (2010) 0.83
Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations. BMC Bioinformatics (2011) 0.83
Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2011) 0.83
Near full-length genome characterization of an HIV type 1 CRF25_cpx strain from Cameroon. AIDS Res Hum Retroviruses (2008) 0.83
Spindle-shaped CD163+ rosetting macrophages replace CD4+ T-cells in HIV-related classical Hodgkin lymphoma. Mod Pathol (2013) 0.82
Chemoresistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells. Mol Cancer (2009) 0.82
Incidence and clinical outcome of cytomegalovirus transmission via breast milk in preterm infants </=31 weeks. Acta Paediatr (2008) 0.82
Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. Eur J Immunol (2012) 0.81
Validation of the 'Marburg bone bank system' for thermodisinfection of allogenic femoral head transplants using selected bacteria, fungi, and spores. Biologicals (2003) 0.81
The mechanism of 3'-azido-2',3'-dideoxythymidine resistance to human lymphoid cells. Int J Mol Med (2003) 0.81
Combination of allele-specific detection techniques to quantify minority resistance variants in hepatitis B infection: a novel approach. J Virol Methods (2013) 0.81
The threat of avian influenza a (H5N1): part II: Clues to pathogenicity and pathology. Med Microbiol Immunol (2007) 0.81
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. J Acquir Immune Defic Syndr (2012) 0.81
West nile virus. Transfus Med Hemother (2013) 0.81
Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients. Antivir Ther (2007) 0.80
Near full-length genome characterization of three additional HIV type 1 CRF13_cpx strains from Cameroon. AIDS Res Hum Retroviruses (2007) 0.80
Prevalence of herpes simplex virus type 2 in different risk groups: thirty years after the onset of HIV. Intervirology (2012) 0.80